Second, in a cohort study following 311 patients with diabetes for a median of two years after transcatheter aortic valve implantation, the use of SGLT2 inhibitors was associated with a more favorable cardiac remodeling as well as improved cardiovascular outcomes [21]. The gene discussed is SLC5A2; the disease is diabetes mellitus.